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To achieve conditional gene expression in the differentiated layers of the epidermis, we generated transgenic
mice with the tetracycline-regulated transactivator proteins, tTA (tetracycline transactivator) and rtTA (reverse
tetracycline transactivator), expressed from the human involucrin promoter. Interaction with tetracycline turns off
or turns on the tTA and rtTA molecules, respectively, allowing for regulation of downstream target genes during
development and postnatally. These transactivator lines were crossed with reporter mice driving LacZ expression
from a tetracycline response element to analyze the speciﬁcity and levels of target gene expression. Quantitative
b-galactosidase experiments demonstrate a 30-fold induction, speciﬁc to epithelial tissues. Immunohistochemistry
results illustrate that the b-galactosidase staining follows that of endogenous involucrin expression. Induction
initiates at embryonic day 14.5 with expression over the entire epidermal surface by E16.5. Together with other
driver lines, expressing tetracycline transactivators in the mitotically active layers of the epidermis, these mice
will allow investigators to speciﬁcally modulate expression of target genes to speciﬁc stages of epidermal
differentiation.
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Toward understanding the in vivo function of proteins, one
powerful approach is to investigate the effect of turning a
gene on or off in temporally and spatially regulated fashion.
Conditional expression is achieved with a tissue-specific
promoter driving an effecter molecule, regulated by tetracy-
cline, to activate a target transgene. This system exists in
two formats: in the tet OFF system, the tetracycline trans-
activator (tTA) binds DNA in the absence of tetracycline,
whereas in the tet ON system, the reverse tTA (rtTA) binds
DNA in the presence of tetracycline. Regulating a gene from
a tet response element (TRE), multiple levels of ectopic exp-
ression can be investigated by crossing with mice that express
tetracycline transactivators in distinct layers of epidermis. This
bi-transgenic system also circumvents the inability to estab-
lish lines due to embryonic or perinatal lethality. (Reviewed
in Lewandoski, 2001; Corbel and Rossi, 2002.).
Mammalian epidermis, a stratified epithelium, is a self-
renewing tissue composed of a population of mitotically
active cells in the innermost basal layer and their derivatives
that travel upward to the skin surface in a linear program of
terminal differentiation (Fuchs and Raghavan, 2002; Nie-
mann and Watt, 2002). Mice with promoters specific to the
basal layer of the epidermis expressing both tet ON and
OFF have been characterized (Keratin 14 (K14): (Xie et al,
1999), Keratin 5 (K5): (Diamond et al, 2000)). There are,
however, no mice with tetracycline effecter molecules
expressed from suprabasal promoters.
Involucrin is a marker of keratinocyte terminal differentia-
tion and is a protein precursor of the terminally differentiated
cornified envelope (CE). Involucrin was one of the first
precursors of the human CE to be identified and molecularly
cloned (Banks-Schlegel and Green, 1981; Eckert and Green,
1986). It is a soluble cytoplasmic protein, rich in glutamine
and glutamic acid, that is a substrate for transglutaminase.
Human involucrin is expressed in the suprabasal cells of the
epidermis and other stratified epithelia, including bladder
and tongue (Rice and Green, 1979). Although the sites of
involucrin expression in mouse are nearly identical, the
onset of expression is slightly later in the upper spinous
layers and inner root sheath of the hair follicle (Djian et al,
1993; Li et al, 2000). Similar to human, mouse involucrin is
detected in tissues with stratified epithelia, including
tongue, palate, uterus, esophagus, and bladder. High levels
of expression are also detected in hyperproliferative epi-
dermis during wound healing (Li et al, 2000).
Regulation of the human involucrin promoter has been
extensively studied both in vitro and in vivo (Carroll and
Taichman, 1992; Carroll et al, 1993; Crish et al, 1998, 2002).
Maximal expression in vitro required 3.7 kb of sequence,
including the first intron (1188 bp), first non-coding exon
and transcription start site (70 bp) and 2473 bp of upstream
sequence (Carroll and Taichman, 1992). Appropriate epithe-
lial expression is observed when this sequence drives exp-
ression of the b-galactosidase enzyme in transgenic mice
(Carroll et al, 1993). Further delineation demonstrated that
the distal region (2473 to 1953) is necessary for surface
epithelial expression and the proximal region (986 to 41)
is necessary for internal epithelial expression (Crish et al,
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1998). Analysis from the Eckert laboratory has identified
many of the binding sites and proteins that regulate the
expression of the human involucrin promoter (Crish et al,
2002 and references within).
To produce conditional expression of genes in the supra-
basal layer of the epidermis, we generated transgenic mouse
lines in which the human involucrin promoter (INVp) drives
expression of the tetracycline-regulated transactivators, tTA,
and rtTA. To characterize the levels of induction of target gene
activation as well as the spatial and temporal expression, we
crossed these lines to reporter mice with the LacZ gene
regulated by a TRE (TRE-LacZ) (Furth et al, 1994).
Here we show that INVp-tTA/TRE-LacZ and INVp-rtTA/
TRE-LacZ double transgenic mice induced by the absence
or presence of tetracycline, respectively, express b-galacto-
sidase specifically in the spinous and granular layers of the
epidermis. This expression pattern is similar to the results
previously obtained with INVp-LacZ transgenic mouse and
confirms the specificity of the tetracycline double-trans-
genic system (Carroll et al, 1993). We extend these studies
by investigating the expression of the involucrin promoter
during development. These mice are publicly available and
in conjunction with other tetracycline-inducible driver mice
should allow the community to address the role of proteins
in specific layers of the epidermis.
Results
Generation and initial characterization of INVp-rtTA and
INVp-tTA mice To create mice expressing the tetracycline
transactivator (tTA) and reverse tTA (rtTA) in the suprabasal
layers of the epidermis, these genes were cloned down-
stream of the human involucrin promoter. This promoter
contains the distal and proximal promoter regions, the first
non-coding exon and the first intron of the human involucrin
gene. This promoter also contains approximately 150 bp of
non-coding SV40 sequence including a small intron (Carroll
et al, 1993). tTA is a fusion of the tet repressor protein (tetR)
with the VP16 activation domain (AD) to activate TRE in the
absence of tetracycline. The re-engineered rtTA protein is a
fusion of a mutated tetR with a trimerized minimal VP16 AD
that activates TRE in the presence of tetracycline (Fig 1A). The
re-engineered rtTA molecule has increased protein stability
and sensitivity to tetracycline with reduced basal activity.
We first determined which lines of PCR positive mice
expressed the effecter mRNA and selected the two INVp-tTA
and INVp-rtTA lines with highest expression for complete
analysis (Fig 1B). The tTA (1.5 kb) and rtTA (1.2 kb) transcripts
are different sizes because of their activation domains. The
INVp-tTA lines express higher levels of transactivator mRNA
as compared to the INVp-rtTA. This may reflect, however, an
ascertainment bias since 23 and 5 founders were identified
for the INVp-tTA and INVp-rtTA lines, respectively.
Transactivation by INVp-rtTA and INVp-tTA is tissue
speciﬁc and regulated by doxycycline (Dox) To analyze
the specificity and levels of target gene expression, INVp-
tTA and INVp-rtTA mice were crossed with reporter mice
expressing the LacZ gene from a TRE (TRE-LacZ) (Furth
et al, 1994). To study relative levels of activation of a target
gene, newborn skin from induced and uninduced INVp-tTA/
TRE-LacZ (INVp-tTA-Z) double transgenics (DT) and INVp-
rtTA/TRE-LacZ (INVp-rtTA-Z) DT were analyzed for expres-
sion of the LacZ mRNA. When induced, the expression of
LacZ mRNA relative to G3PDH as control for loading is as
follows: INVp-rtTA line INV3: 1.00; INVp-rtTA line INV4: 1.50;
INVp-tTA line I3:3.83; INVp-tTA line I4: 3.63. Note that the
INVp-rtTA tet-ON lines are denoted as INV3 and INV4 and
the INVp-tTA tet-OFF lines are denoted as I3 and I4. Com-
paring the highest expressors for each construct, INVp-
tTA line I3 express approximately 2.5 fold higher levels of
LacZ mRNA than the INVp-rtTA line INV4 (Fig 2A). Under
uninduced conditions, none of the lines activates appreciable
amounts of LacZ transcription (data not shown). The levels of
LacZ activity are proportional but not strictly correlated to the
levels of transactivator transcript seen in Fig 1B.
To analyze tissue specificity and regulation by Dox of
target gene activation, b-galactosidase enzyme activity is
assayed in involucrin expressing (skin, tongue) and non-
expressing tissue (liver) of INVp-tTA-Z and the INVp-rtTA-Z
DT in the presence and absence of Dox. Skin samples
for every line show at least 30-fold induction of the
b-galactosidase enzyme in the induced versus uninduced
state. The levels of expression in the uninduced state were
essentially at background levels, suggesting extremely tight
control of induction. As was observed for the levels of LacZ
mRNA, the highest levels of expression were from INVp-
rtTA-Z DT line INV4 and INVp-tTA-Z DT line I3. Similarly, the
INVp-tTA-Z DT line I3 skin sample had approximately 2-fold
higher levels of b-galactosidase enzyme activity than the
INVp-rtTA-Z DT line INV4 (Fig 2B). Utilizing different pro-
moters, previous comparisons between tet-OFF and tet-ON
mice have noted an almost 10-fold difference in the levels of
expression. One possible explanation for the higher levels of
Figure1
Generation and characterization of INV-tTA and INV-rtTA trans-
genic mice. (A) Diagram of the INVp-tTA and INVp-rtTA transgene
constructs. The 3.9 kb involucrin promoter was cloned upstream of the
tTA and rtTA effecter molecules. Size of each part of the construct is
given below the construct. TetR: Tetracycline repressor; FFF AD:
trimerized minimal VP16 activation domain; VP16 AD: VP16 activation
domain. SBI: SnaBI, ERV: EcoRV, HIII: HindIII, SI: SalI, SII: SacII, BZI:
BstZ17I, RI: EcoRI. (B) Northern blot analysis of tTA and rtTA expression
levels for INV3 and INV4 (rtTA at 1.2 kb) and I3 and I4 (tTA at 1.5 kb)
hybridized with a probe for SV40 poly A. G3PDH hybridization is used
to normalize the levels of mRNA for each lane.
314 JAUBERT ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
b-galactosidase enzyme activity for induced INVp-rtTA-Z
DT mice may be the reengineered rtTA molecule.
Transactivation of the LacZ promoter also occurred in the
tongue, which expresses involucrin, but to almost a 10-fold
lesser extent than in the skin (Fig 2B). This may reflect the
lower percent of Involucrin positive cells per gram of tissue in
the tongue than in the skin. For all of the samples, the level of
b-galactosidase enzyme in the liver, a non-involucrin-expres-
sing tissue, was similar to background levels (data not shown).
Under identical conditions, we directly compared the le-
vels of luminescence in the skin of INVp lines with the Glick
laboratory K5p-tTA line 1216, which yielded the highest
levels of b-galactosidase enzyme of all lines reported. The
K5p-tTA produced 5.9-fold higher levels of activation than
the INVp-tTA line I3 (821 vs 138 RLU per mg protein) and
11.6-fold higher levels of activation than the INVp-rtTA line
INV4 (821 vs 70). The variance between these lines may
reflect the number of cells expressing the promoter or the
strength of the promoter. Importantly, these driver mice
have levels of activation within an order of magnitude of
each other, allowing an investigator to modulate the levels
and patterns of expression of specific proteins.
Dose dependence of INVp-rtTA-Z and INVp-tTA-Z DT To
analyze the levels of Dox necessary to achieve activation of
the INVp-rtTA-Z DT (tet-ON), INV4 mice were provided with
a 25-fold range dose of Dox for 1 wk; i.e., 0.4, 2, or 10 g per
liter. At the end of this week, the levels of LacZ expression
were quantified from a skin biopsy. For all three doses, the
level of LacZ expression was similar and statistically
indistinguishable (46 RLUper mg protein). This is consistent
with the prediction from the original report by Bujard’s
laboratory that the newly engineered rtTA-M2 molecule will
be induced to the same level with 10-fold lower Dox than
was previously utilized. These INVp-rtTA-Z DT mice were
switched to regular drinking water and biopsies were taken
at day 2 and day 5. Only the animals kept on the lowest
levels (0.4 g per liter) showed a significant decline in the
level of expression of LacZ by day 2 (12 RLU per mg protein).
Mice on the medium and high levels showed a modest
decline by day 2 (28 RLU per mg protein and 36 RLU per mg
protein for 2 and 10 g per liter, respectively). Finally, by day 5
mice receiving all three doses had significant declines in
LacZ gene expression almost reaching background levels
of expression (7 RLU per mg protein). These results indicate
that all three levels of Dox (0.4, 2, and 10 g per liter) will achi-
eve the same level of activation. If an investigator would like
to reverse the downstream gene activation, however, this
can most rapidly be achieved with the lowest level of Dox.
This same experiment was performed on the INVp-tTA-Z
DTwith 1 w on the 25-fold range of Dox (0.4, 2, and 10 g per
liter) and switched to regular water while monitoring gene
expression from biopsied skin. Again, all three levels of Dox
were able to achieve complete suppression of gene ex-
pression, indicating that the lowest level of Dox is sufficient
to regulate downstream gene expression. For the INVp-tTA-
Z DTs, however, there was still no gene expression 5 d after
the switch to regular drinking water. This continuing
repression of the INVp-tTA-Z DT even with low levels of
Dox may prove difficult for investigators who want to rapidly
turn back on gene expression.
Localization of b-galactosidase expression in INVp-rtTA-
Z and INVp-tTA-Z DT mice mimics endogenous involu-
crin expression Consistent with the staining data of adult
mice from the Watt laboratory, the involucrin antibody
reacts with protein in the granular layer of the epidermis and
the inner root sheath of the hair follicle of the newborn
mouse (Fig 3A) (Li et al, 2000). When crossed with TRE-
LacZ mice and induced, both newborn INVp-tTA-Z and
INVp-rtTA-Z DT show b-galactosidase enzyme activity con-
sistent with the expression of the endogenous involucrin
protein (Fig 3B, C). There are distinctions, however, between
the DT-induced mice. First, the INVp-tTA-Z DT have positive
Figure 2
Differences in the levels of induction obtained between lines of
INVp-rtTA-Z and INVp-tTA-Z DT mice. Levels of transactivation of the
INVp-rtTA and INVp-tTA mice are ascertained by crossing them with the
TRE-LacZ responder mice with or without Dox. (A) Northern blot
analysis of LacZ mRNA (4.2 kb) expression from skin of induced
newborn INVp-rtTA-Z DT (lines INV3 and INV4) and INVp-tTA-Z DT
(lines I3 and I4). G3PDH hybridization is used to normalize the levels of
mRNA for each lane. (B) Tissue-specific transactivation of b-galacto-
sidase enzyme is activated by Dox in INVp-rtTA-Z DT (lines: INV3 and
INV4). On the reverse, tissue-specific transactivation of b-galactosi-
dase enzyme is induced by the absence Dox in INVp-tTA-Z DT (lines: I3
and I4). Tissue type, line, and presence or absence of Dox is indicated
on the X-axis. The shaded bars are the readings in the induced state
and the unshaded bars are the uninduced state. The height of the bar
represents the average of four mice with standard deviations indicated.
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cells in the lower spinous cells, whereas the INVp-rtTA-Z DT
expression is constrained to the upper spinous cells. Sec-
ond, only the INVp-tTA-Z DTs show prominent expression in
the hair follicles. Third, the time required for strong staining
of the sections is less for the INVp-tTA lines than for the
INVp-rtTA, consistent with the levels of activation observed
above. When the INVp-rtTA-Z and INVp-tTA-Z DTs are
uninduced, no b-galactosidase enzyme activity is detected
in situ (data not shown). The expression in the tongue of
INVp-rtTA-Z and INVp-tTA-Z DTs is also faithful to endo-
genous involucrin, with staining in suprabasal cells of both
the dorsal and ventral surfaces of the tongue (Fig 3D, E).
Endogenous involucrin expression and b-galactosidase
expression in INVp-rtTA-Z and INVp-tTA-Z DTs during
development Before analyzing the pattern of these lines in
development, we first investigated the endogenous involu-
crin expression. We first detect involucrin mRNA at E15.5
with upregulation at E16.5 (Fig 4A). Involucrin is expres-
sed later than keratin 1 or 10 and after initial strati-
fication but before barrier acquisition (Byrne et al, 1994;
Hardman et al, 1998). Involucrin protein is expressed in the
upper spinous cells throughout development at E15.5,
E16.5 and E17.5 (Fig 4B).
To analyze the pattern of expression, we performed
whole-mount staining on INVp-tTA-Z and INVp-rtTA-Z DT.
Expression of the b-galactosidase enzyme is first detected
in the head and whisker pads at E14.5. The expression of
endogenous involucrin was not detected on the northern
blot at E14.5 because the embryo heads were removed
prior to processing the samples for mRNA. The b-gala-
ctosidase enzyme signal spreads across the lateral and
ventral body surfaces with a striped pattern at E15.5. By
E16.5 the entire surface of the embryo possesses b-
galactosidase enzyme activity (Fig 4C, D). The striped
expression pattern at E15.5 could indicate some position
effect variegation. The same pattern, however, was ob-
served with multiple lines and from both constructs.
Although the involucrin promoter driving the tTA and rtTA
effecters gave similar expression patterns, the time required
for staining was less for tTA than for the rtTA animals,
consistent with the quantitative data presented in Fig 2.
Discussion
The bitransgenic tetracycline system enables investigators
to query the function of proteins by ectopically expressing
Figure 3
Location of Involucrin protein expression in newborn skin in wild-
type mice is consistent with b-galactosidase expression in INVp-
tTA-Z and INVp-rtTA-Z DT mice. (A) Anti-involucrin immunohisto-
chemistry of paraffin embedded sections of wild-type newborn mouse
skin. (B–E) Pattern of expression of the INV-rtTA and INV-tTA driver
mice characterized by crossing with responder TRE-LacZ mice and
analyzing the b-galactosidase expression in newborn skin or tongue of
double transgenics, as indicated. Dotted line indicates the basement
membrane. White dotted line indicates that an area of the dermis with
no signal has been cropped.
Figure4
Endogenous involucrin expression during development and whole-
mount b-galactosidase expression in INVp-rtTA-Z and INVp-tTA-Z
DT. (A) Northern blot analysis of Involucrin mRNA expression (1.9 kb)
in wild-type mice during development from E10.5 to E16.5. A signal is
first detected at E15.5. G3PDH probe is a control for loading. (B) Anti-
involucrin immunohistochemistry of paraffin-embedded sections of
wild-type E15.5, E16.5 and E17.5 mouse skin. (C, D) Developmental
expression pattern of INVp-tTA and INVp-rtTA lines, determined by
crossing with the responder TRE-LacZ line at E14.5, E15.5, and E16.5.
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them in spatially and temporally regulated fashions. The
power of this system is greatly increased when multiple
driver mice are available to direct expression at discrete
points in the differentiation pathway of a specific tissue. We
report here the characterization of tet ON and tet OFF trans-
activators driven by the human involucrin promoter and
expressed in epidermal cells that have withdrawn from the
cell cycle. Utilizing these mice should complement studies
performed with keratin 5 promoter driving the tetracycline-
regulated transactivators in mitotically active epidermal cells
(Diamond et al, 2000). Additional lines driving expression of
the tetracycline transactivators from the well-characterized
keratin 1 or keratin 10 and loricrin promoters would give a
full complement of expression for target genes in the
epidermis (Greenhalgh et al, 1993; DiSepio et al, 1999).
By creating one line of responder mice expressing a
target gene from a tetracycline responder element, one
could then cross this line with the many driver mice for ex-
pression in the epidermis. Not only would this finely dissect
the role of a given protein in the layers of the epidermis, but
this systematic study might also resolve some of the
phenotypic discrepancies observed when the same protein
is expressed from different promoters. For example, two
groups investigated the ectopic expression of desmoglein 3
(Dsg3) in the epidermis and found non-overlapping pheno-
types (Elias et al, 2001; Merritt et al, 2002). These transgenic
mice, besides having unique integration sites in the genome
also had differences in the promoter utilized (K1 vs Inv), tag
on protein, background strain of mice, copy number and the
utilization of mouse vs. human sequences. Creating one
responder mouse expressing Dsg3 to mate with driver mice
from K1 and Inv promoters could standardize many of these
inherent genetic differences.
Gene activation from the tet-OFF INVp-tTA line I3 is
2–2.5-fold higher than the levels achieved with the tet-ON
INVp-rtTA line INV4 as measured by b-galactosidase
enzyme activity and the levels of LacZ mRNA transcription.
These levels are relative to the levels of transactivator
transcript expressed by each line. These results support the
results from studies in Saccharomyces cerevisiae that the
new transactivator, rtTA-M2 results in higher levels of gene
activation with no background expression in the absence of
Dox (Urlinger et al, 2000).
Although INVp-rtTA/LacZ DT showed the same level of
activation of LacZ expression over a 25-fold range dose of
Dox (0.4–10 g per liter), only the mice administered the
lowest dose (0.4 g per liter) showed a significant decline in
LacZ expression 2 d after the switch to regular drinking
water. By 5 d on regular drinking water, all of the INVp-rtTA/
LacZ DT expressed only background levels of LacZ.
Therefore, if the investigator would like to reverse down-
stream gene activation, the lowest levels of Dox (0.4 g per
liter) should be used. In contrast, for the INVp-tTA-Z DT no
gene expression 5 d after the switch to regular drinking
water was observed even at the lowest levels of Dox tested.
The expression of the INVp-tTA and INVp-rtTA mice
mimics the endogenous expression of the involucrin
promoter with expression in the upper spinous and granular
cells of the epidermis. INVp-tTA I3 gives the strongest level
of expression and is the only one to show expression in the
hair follicle. Analysis of involucrin mRNA and protein
expression during development indicates that these driver
lines mimic the endogenous expression.
Preliminary results from our laboratory indicate that the
levels of transactivator produced by the INVp-tTA and INVp-
rtTA lines are both sufficient to activate gene expression
and produce phenotypes from our TRE-Klf4 lines. Further
studies to dissect the epidermal and hair follicle phenotypes
of these DT are underway (J.J. and J.S. unpublished data).
Other investigators will have additional experimental
needs for these lines and will need to determine for specific
developmental stages how rapidly the lines can be turned
ON and OFF with the administration or removal of Dox.
These results will allow investigators to specifically tailor
their experimental design and to ascertain the confidence of
their conclusions.
These mice driving the tetracycline transactivators from
the involucrin promoter are now publicly available to modu-
late expression in skin. These mice, in conjunction with
other driver lines, should prove useful to study epidermal
differentiation and development as well as carcinogenesis
and wound healing.
Materials and Methods
Generation of INVp-rtTA and INVp-tTA constructs and mice The
Tet-Off protein (tTA) encodes the Escherichia coli tetracycyline tet
repressor (tetR) protein fused to the VP16 activation domain of
herpes simplex virus. The Tet-On protein (rtTA) has been re-
engineered by Hillen and colleagues, who altered five amino acids
in the tetR and reduced the VP16 activation domain to a minimal 12
amino acids (known as the F domain), which is trimerized to 36
amino acids (FFF) (Urlinger et al, 2000). The involucrin promoter
utilized contains 3.7 kb of DNA upstream of the first coding exon of
the gene and approximately 150 bp of non-coding SV40 sequence
including a small intron (Carroll et al, 1993) (Fig 1A).
Human Involucrin promoter was cut from the original vector
(pH3700-pL2) with SalI–NotI and cloned into the same sites in
pTRE2 vector (Clontech, Palo Alto, California) to increase the
number of available sites (Carroll et al, 1993). INVp was cut out of
this new vector to make two constructs: (i) INVp-rtTA construct, INVp
digested with EcoRV–SacII, and subcloned in SnaBI–SacII compa-
tible ends in pUHDrtTA2S-M2 (Urlinger et al, 2000); and (ii) INVp-tTA
construct: INVp digested with EcoRV–EcoRI and subcloned in
BstZ17I–EcoRI compatible ends in pTet-Off vector (Clontech). Both
constructs were purified by CsCl gradient (Lofstrand, Gaithersburg,
Maryland). To excise the insert, 30 mg of DNA was digested with
HindIII, cleaving at the 50 end of the human involucrin promoter and
30 to the SV40 poly A. For the INVp-tTA vector, the DNA was
additionally digested with DrdI to make the vector backbone more
easily distinguished from the insert for gel purification. Inserts were
purified (QIAGEN, Valencia, California) and injected into FVB/N one-
cell eggs following standard pronuclear injection (Hogan et al, 1986).
Positive founders were identified by PCR and maintained on FVB/N
background. For the INVp-tTA construct, 23 founders were identified
as positive. For the INVp-rtTA construct, 5 founders were identified
as positive. Genotyping of embryos was done by PCR using the
following primers: INVp-tTA transgene: 50-AGGGAAGAGGGGATGC-
TAAA, 50-CCATCGCGATGACTTAGT; INVp-rtTA transgene: 50-AGG-
GAAGAGGGGATGCTAAA, 50-AGAGCACAGCGGAATGACTT. LacZ
primers were previously published (Diamond et al, 2000). All studies
on animals were approved by the animal care and use committee
and made following their recommendations in our AALAC-accre-
dited animal facility.
Characterization of the INV-tTA and INV-rtTA transgene
expression INVp-tTA and INVp-rtTA lines were time-mated with
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mice expressing LacZ regulated by a TRE (TRE-LacZ) (gift from
L. Henninghausen and A. Glick) (Furth et al, 1994). The morning
of vaginal plug detection was taken as embryonic day (E) 0.5.
The mice were maintained either with or without the tetra-
cycline derivative Dox as indicated in text or figures beginning at
gestational day E10.5. Dox was administered in the drinking water
at 2 g per liter in 5% sucrose for all experiments except the time
course of induction in which Dox was administered in the drinking
water at 0.4, 2, or 10 g per liter.
RNA isolation and northern blot analyses For newborns, E15.5,
and E16.5 embryos, skin from the body was isolated by dissection.
At E12.5, E13.5 and E14.5, heads and inner organs were removed
prior to tissue processing. At E10.5 and E11.5, heads were
removed and bodies used for tissue sampling. All samples were
snap frozen in liquid nitrogen. Tissue was pulverized, homogenized
in Trizol (Invitrogen, Grand Island, New York) and RNA was
extracted following manufacturer’s recommendations. Approxi-
mately 15 mg RNA was loaded in every lane and visualized by EtBr
for integrity of the samples. Blots were hybridized with LacZ probe
(amplified by PCR on cDNA with primers: 50-ACCAGCGAAATG-
GATTTTTG and 50-TAGCGGCTGATGTTGAACTG) with SV40 poly
Aþ probe (digested with BamHI and HindIII from rtTA2SM2 and
gel purified as a 450 bp product) or with G3PDH probe (amplified
by PCR on cDNA with primers: 50-ACCACAGTCCATGCCATCAC
and 50-TCCACCACCCTGTTGCTGTA) as loading control. Signals
were quantified using Molecular Dynamics Phosphorimager and IQ
analysis software (Amersham, Piscataway, New Jersey).
Detection of b-galactosidase To quantitate b-galactosidase en-
zyme activity, tissues were homogenized in a buffer contain-
ing 100mM potassium phosphate pH7.8, 0.2% Tween 20, 1 mM
dithiothreitol, and the cleared supernatant was reacted with a
luminescent substrate reagent using a Luminescent b-galactosi-
dase detection kit (Invitrogen). b-galactosidase activity was meas-
ured using a Turner Designs 20/20 luminometer and expressed as
relative light units per microgram of protein. Readings were
performed at 49.9% sensitivity.
Histochemical staining for b-galactosidase activity was per-
formed at 371C with 5-bromo-4-chloro-3-inolyl-D-galactopyranoside
(X-gal) substrate on frozen sections from newborn mice as previously
described (Diamond et al, 2000). Images were acquired with
Openlab software using an Axioskop microscope (Zeiss, Thorn-
wood, New York) equipped with a digital Axiocam camera (Zeiss).
Embryos were collected at E14.5, E15.5 and E16.5 and pre-
fixed for 30 min in 4% paraformaldehyde. Whole-mount staining
with X-gal substrate was performed at 371C as previously
described (Byrne et al, 1994). After post-fixing in 4% paraformal-
dehyde, embryos were photographed under a MZFLIII dissecting
microscope (Leica, Bannockburn, Illinois) as above.
For the timed induction studies, 5 mm diameter skin biopsies
were removed from the dorsal surface and sutured closed.
Subsequent days, biopsies were removed from an area at least
2 cm from any previous area biopsied.
Immunohistochemistry Backskin samples from wild-type em-
bryos were taken at E15.5, E16.5 and E17.5 and at newborn stage,
fixed overnight in 4% PFA /PBS and embedded. Paraffin sections
were hybridized with rabbit polyclonal antibodies against Involucrin
(1:500) (Covance, Berkeley, California). Biotinylated secondary
antibody (1:200) was used with Vectastain ABC kit and DAB
substrate (Vector Laboratories, Burlingame, California).
The authors would like to thank Cherry Yang for assistance with the
animal care and genotyping. Michael Cichanowski assisted in
preparing the figures. Esther Fine assisted in the initial characteriza-
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